Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Zambart
Street 1: Ridgeway Campus
Street 2: Nationalist Road
City: Lusaka
Post Code:
Country: Zambia
Phone: +260 211 257215
Organization Email:
Web Site:
Other Online Presence:

Focal Point Contact Information

Salutation: Dr
First Name: Alwyn
Last Name: Mwinga
Title: Chief Executive Officer
Phone: +260977640900

Alternate Focal Point Contact Information

Salutation: Dr
First Name: Helen
Last Name: Ayles
Title: Research Director
Phone: +260966746796

General Information

Board Constituency: Technical agencies
Is your organization legally registered in your country: Yes
If yes, please enter your registration number:
Organization Type - Primary: Academic / Research Institution
Organization Type - Secondary: None
Organization Description:
Zambart is a research organization that has conducted research on tuberculosis for the last 22 years. From an initial focus on the impact of HIV on the clinical presentation and outcome of TB, the research conducted by Zambart has expanded to include the evaluation of new technologies and diagnostics, stigma, urban control of TB, feasibility of IPT, economic impact of TB, household level interventions with combined HIV and TB care and the impact of a combination of HIV prevention on community incidence of HIV to name a few.
Zambart collaborates with the National TB Program to strengthen the control of TB and participates in several national TB working groups such as the TB/HIV Working Group and the Laboratory Working Group and the Advisory committee for the national TB Prevalence Survey.
Do you know about the UNHLM declaration:

Specializations / Areas of Work

Research and Development

Other Organization Information

Total number of staff in your organization: 100 +
Number of full-time staff who are directly involved with TB: 11 - 25
Number of part-time staff who are directly involved with TB: 6 - 10
Number of volunteers who are directly involved with TB: 11 - 25
How did you hear about the Stop TB Partnership: Involvement in TB control provision
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Network with other partners
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
Zambart contributes to the national TB programme through the participation of staff on the national TB technical working groups and advisory bodies, conducting surveys on behalf of the NTP, contributing to evidence based decision making by providing information from implementation research.

Geographical Reach

Which country is your headquarters located in: Zambia
Which countries do you do operate in:
(This includes countries you are conducting activities in)


Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

TB Care Delivery:
Zambart has carried out several studies that were designed to understand factors impacting on TB control in urban areas, the impact of TB and HIV-related stigma and discrimination, obstacles to effective TB diagnosis in hospital settings and the economic impact of TB to name a few. Zambart was one of two countries that conducted a study to investigate the impact of household level interventions on combined TB and HIV care (ZAMSTAR). This study involved close linkages with the community and as a result Zambart has developed very strong competencies in the area of community based research. Part of this study involved conducting a TB prevalence survey in the target communities and this experience was used as the country planned for the first ever national TB Prevalence Survey that is currently ongoing. Zambart staff are active in the Advisory Committee for this survey.

Drug-Resistant TB:
Zambart is active in the area of MDR surveillance and was contracted by the Ministry of Health to carry out a national Drug resistance survey in 2008.

Zambart has been in the fore front in undertaking studies linked to the implementation of TB/HIV activities beginning with the ProTEST initiative, investigating the feasibility of TB preventive therapy and barriers to the uptake of TB/HIV interventions. Zambart is a member of the National TB/HIV Coordinating Committee and contributes to the development of TB/HIV interventions at a national level. Zambart is currently implementing a trial on the impact of a package of HIV prevention interventions on community level HIV incidence, the PopART Trial

Laboratory Strengthening:
One of the outcomes of the ZAMSTAR Study was the development of a containerized laboratory that is now marketed as the ZAMLab. Zambart staff are active in the national Laboratory working group.

New Diagnostics:
Zambart has evaluated several new diagnostics in collaboration with FIND and DFID. More recently Zambart was the recipient of two TB REACH grants from WHO for the implementation of Gene Xpert. Zambart staff are active in the Laboratory Working Group that has developed the guidelines for the scale up of Gene Xpert nationally.

New TB Vaccines:
Based on the extensive experience in conducting clinical trials and working at community level Zambart is available to function as a clinical trial site for new vaccine trials.

Zambart is one of the lead organizations carrying out operational research in Zambia and works closely with the Ministry of Health to implement research that contributes to the development of policy and guidelines. In 2009/2010, at the request of the Ministry of Health, Zambart piloted the use of IPT in health clinics. IPT is now included as part of the guidelines for TB/HIV management in Zambia.


Declaration of interests:
No conflicts of interest were delacred.

Application date: March 25, 2014
Last updated: June 16, 2014